| 000 | 01740 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514002854.0 | ||
| 264 | 0 | _c20020221 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a1042-8194 | ||
| 024 | 7 |
_a10.3109/10428190109057928 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarella, A M | |
| 245 | 0 | 0 |
_aTreatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cJan 2001 |
||
| 300 |
_a295-303 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfections _xetiology |
| 650 | 0 | 4 |
_aLeukemia, Myeloid _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aCascavilla, N | |
| 700 | 1 | _aGreco, M M | |
| 700 | 1 | _aMelillo, L | |
| 700 | 1 | _aSajeva, M R | |
| 700 | 1 | _aLadogana, S | |
| 700 | 1 | _aD'Arena, G | |
| 700 | 1 | _aPerla, G | |
| 700 | 1 | _aCarotenuto, M | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 40 _gno. 3-4 _gp. 295-303 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428190109057928 _zAvailable from publisher's website |
| 999 |
_c11356006 _d11356006 |
||